Would you consider dual antiplatelet therapy for stroke prevention for ICAD in patients with a history of SAH?

It depends on the strength of the indication for DAPT and the cause of SAH.

It is important to keep things in perspective: the absolute risk reduction from DAPT for secondary stroke prevention in the POINT, CHANCE, and THALES trials was small (on the order of 1-3% absolute risk reduction) for minor ...

If the indication is strong, e.g., high-risk TIA, minor stroke, or acute MI, I would do so for a limited period of time. Aneurysms should be operated on depending on size and location. Although antiplatelet therapy is not likely to make an aneurysm bleed.